Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS.
Journal
Neurology. Clinical practice
ISSN: 2163-0402
Titre abrégé: Neurol Clin Pract
Pays: United States
ID NLM: 101577149
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
30
1
2021
Statut:
ppublish
Résumé
Delayed-release dimethyl fumarate (DMF) has demonstrated robust efficacy in treating patients with relapsing-remitting multiple sclerosis. Decreases in absolute lymphocyte count (ALC) are a well-known pharmacodynamic effect of DMF treatment, but lymphocyte recovery dynamics are not well characterized after discontinuation of DMF. Data sources included the Biogen DMF integrated clinical trial data set, a retrospective US chart abstraction study, and data from MSBase. We assessed rate and time course of lymphocyte reconstitution after DMF discontinuation. The majority of patients who developed lymphopenia while treated with DMF and subsequently discontinued treatment experienced ALC reconstitution. The median time to reach ALC ≥0.8 × 10 The majority of patients who discontinued DMF due to lymphopenia experienced ALC reconstitution within 2-4 months following DMF discontinuation. This may help guide clinicians in managing patients who develop lymphopenia during DMF treatment. Prolonged lymphopenia on DMF treatment is associated with slow lymphocyte recovery after DMF discontinuation.
Sections du résumé
BACKGROUND
BACKGROUND
Delayed-release dimethyl fumarate (DMF) has demonstrated robust efficacy in treating patients with relapsing-remitting multiple sclerosis. Decreases in absolute lymphocyte count (ALC) are a well-known pharmacodynamic effect of DMF treatment, but lymphocyte recovery dynamics are not well characterized after discontinuation of DMF.
METHODS
METHODS
Data sources included the Biogen DMF integrated clinical trial data set, a retrospective US chart abstraction study, and data from MSBase. We assessed rate and time course of lymphocyte reconstitution after DMF discontinuation.
RESULTS
RESULTS
The majority of patients who developed lymphopenia while treated with DMF and subsequently discontinued treatment experienced ALC reconstitution. The median time to reach ALC ≥0.8 × 10
CONCLUSIONS
CONCLUSIONS
The majority of patients who discontinued DMF due to lymphopenia experienced ALC reconstitution within 2-4 months following DMF discontinuation. This may help guide clinicians in managing patients who develop lymphopenia during DMF treatment. Prolonged lymphopenia on DMF treatment is associated with slow lymphocyte recovery after DMF discontinuation.
Identifiants
pubmed: 33510947
doi: 10.1212/CPJ.0000000000000800
pii: NEURCLINPRACT2019043323
pmc: PMC7837440
doi:
Types de publication
Journal Article
Langues
eng
Pagination
510-519Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI144288
Pays : United States
Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Neurol Clin Pract. 2016 Jun;6(3):220-229
pubmed: 27347439
Curr Med Res Opin. 2014 Feb;30(2):251-62
pubmed: 24131282
Ther Adv Neurol Disord. 2019 May 08;12:1756286419843450
pubmed: 31105768
Acta Neurol Scand. 2018 Jun;137(6):623-625
pubmed: 29205270
Mult Scler Relat Disord. 2018 May;22:27-34
pubmed: 29524759
Mult Scler. 2006 Dec;12(6):769-74
pubmed: 17263005
N Engl J Med. 2012 Sep 20;367(12):1087-97
pubmed: 22992072
Eur J Neurol. 2015 Apr;22(4):664-71
pubmed: 25557371
Lancet. 2008 Oct 25;372(9648):1463-72
pubmed: 18970976
N Engl J Med. 2012 Sep 20;367(12):1098-107
pubmed: 22992073
Mult Scler. 2017 Feb;23(2):253-265
pubmed: 27207449
Neurology. 2019 Apr 9;92(15):e1724-e1738
pubmed: 30918100
BMC Neurol. 2015 Jul 08;15:108
pubmed: 26152311
Mult Scler J Exp Transl Clin. 2015 Jan-Dec;1:
pubmed: 26550483
N Engl J Med. 2013 Apr 25;368(17):1659-61
pubmed: 23614605